Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 2/20 | 0.35 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.35 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.34 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491036 | 0.80 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL5257616 | 0.79 | GRIN2B (0.41) | CHIAGRIN1GRIN2BACHE | |
| SCHEMBL5488983 | 0.77 | CRHR1 (0.45) | CHIT1CHIACHI3L1CHI3L2CRHR1 | |
| SCHEMBL5492086 | 0.76 | TP53 (0.36) | CRHR1 | |
| SCHEMBL5492348 | 0.74 | CRHR1 (0.43) | CHIT1CHIACHI3L1CHI3L2CRHR1 | |
| SCHEMBL5498704 | 0.74 | TP53 (0.36) | CRHR1 | |
| SCHEMBL5258080 | 0.73 | GRIN2B (0.40) | GRIN1GRIN2BACHE | |
| SCHEMBL5488610 | 0.73 | CRHR1 (0.34) | CRHR1ACHE | |
| SCHEMBL5492837 | 0.71 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL5494540 | 0.70 | SMN1; SMN2 (0.34) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | claimed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CHIT1 2077/4885CHIA 2958/4885CHI3L1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.